For its first fiscal quarter (ending March 31), Globus Medical Inc (NYSE: GMED) has reported a -110% decline in E.P.S. from $0.49 a year ago to $-0.05 in the current quarter. This result fell short of the consensus estimate of $0.74 by $-0.79. For the latest four quarters through March 31, E.P.S. were $0.64 versus $2.01 for the same period a year ago — a decline of -68%.
Recent Price Action
Globus Medical Inc (NYSE: GMED) stock enjoyed a large increase of 2.2% on 5/7/24. The stock closed at $51.36. Moreover, this advance was accompanied by unusually high trading volume at 183% of normal. The stock has performed in line with the market over the last nine months and has risen 1.5% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, GMED is expected to continue to be a modest Value Builder.
Globus Medical has a current Value Trend Rating of C (High Neutral). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Globus Medical has a good Appreciation Score of 76 but a neutral Power Rating of 41, producing the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment